- Plus Therapeutics has initiated manufacturing activities and technology transfer with SpectronRx to support late-stage clinical production of Rhenium-186 and REYOBIQ.
- The agreement adds a second GMP manufacturing site and expands the company’s multi-partner supply chain alongside Radiomedix and Telix Pharmaceuticals.
Plus Therapeutics, Inc. has begun manufacturing activities and technology transfer with SpectronRx under an existing Master Services Agreement, supporting late-stage clinical manufacturing of Rhenium-186 and its investigational therapy REYOBIQ for central nervous system cancers.
The collaboration establishes SpectronRx as a second GMP manufacturing site, complementing Radiomedix, while Rhenium-186 isotope supply will continue through Telix Pharmaceuticals. The arrangement is designed to strengthen the company’s multi-partner supply chain and support clinical development requirements.
Under the agreement, SpectronRx will receive the REYOBIQ manufacturing process, including isotope processing methods, analytical techniques, and regulatory expertise. Its Indiana facility will provide on-demand manufacturing capabilities for both Rhenium-186 isotope production and REYOBIQ drug manufacturing within a single site, with the aim of improving coordination and simplifying logistics across the radiopharmaceutical production process.
The initiative comes as Plus Therapeutics advances REYOBIQ into late-stage development, with a stated target of completing manufacturing scale-up for clinical supply needs by 2026. The company is working to expand production capacity to support this stage of development.
“We are focused on advancing our REYOBIQ development, including progress towards our 2026 target milestone to complete manufacturing scale-up for REYOBIQ late-stage clinical supply needs.”
Marc H. Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics
